Building on the success of Bristol-Myers Squibb / Ono Pharmaceutical’s PD-1 inhibitor Opdivo in the recurrent renal cell carcinoma setting, combination regimens that include immune checkpoint inhibitors (e.g., Opdivo plus Yervoy) look set to revolutionize the treatment of advanced disease. Angiogenesis inhibitors remain a key feature in treatment, as Exelixis /Ipsen’s Cabometyx joins Pfizer’s Sutent and Novartis’s Votrient as a first-line treatment. The entry and increased market share of Cabometyx and Opdivo in this setting are beginning to shift Pfizer’s Inlyta, the combination of Eisai’s Lenvima / Kisplyx with Novartis’s Afinitor, and single-agent mTOR inhibitors to later lines. Furthermore, following Sutent’s FDA approval for high-risk early-stage (stage I-III) disease, multiple immune checkpoint inhibitors are anticipated to transition into early-stage treatments. As the highly competitive renal cell carcinoma market becomes increasingly fragmented, the developer of an efficacious and tolerable therapy could reap substantial commercial rewards.

Questions Answered:

  • How large are the early-stage and advanced or metastatic drug-treatable populations? Will drug-treatment rates change over time?
  • How is renal cell carcinoma currently treated, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • Who are the key players developing combination therapies for renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?
  • Which emerging therapies do we forecast to enter each renal cell carcinoma setting? What uptake and sales will these therapies secure?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Twenty country-specific interviews with thought leaders (medical oncologists and urologists).

Key companies: Bristol-Myers Squibb/Ono Pharmaceutical, Merck & Co./MSD, Exelixis/Ipsen, and Pfizer.

Key drugs: Opdivo, Keytruda, Cabometyx, and Inlyta.

Population segments in market forecast: Early-stage (stage I-III) renal cell carcinoma, first-line advanced or metastatic renal cell carcinoma, second-line advanced or metastatic renal cell carcinoma, third-line advanced or metastatic renal cell carcinoma, and fourth-line advanced or metastatic renal cell carcinoma.

Emerging therapies: Phase III: 8 drugs; Phase II: 18 drugs; coverage of select Phase I and preclinical products.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
    • Key Updates
      • December 2019
      • July 2019
      • May 2019
      • March 2019
      • December 2018
      • October 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Renal Cell Carcinoma?
        • What Factors Are Constraining the Market for Renal Cell Carcinoma?
      • Segment-Specific Trends
        • Early-Stage (Stage I-III) Renal Cell Carcinoma
        • First-Line Advanced or Metastatic Renal Cell Carcinoma
        • Second- and Later-Line Advanced or Metastatic Renal Cell Carcinoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
        • Staging and Classification
        • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Renal Cell Carcinoma
        • Recurrent Incident Cases of Renal Cell Carcinoma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • mTOR Inhibitors
      • Medical Practice
        • Early-Stage Renal Cell Carcinoma: Stages I-III
        • First-Line Advanced or Metastatic Renal Cell Carcinoma: Stage IV
        • Second-Line Advanced or Metastatic Renal Cell Carcinoma
        • Third- and Fourth-Line Advanced or Metastatic Renal Cell Carcinoma
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Renal Cell Carcinoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • Cytokines
        • Histone Deacetylase Inhibitors
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Renal Cell Carcinoma Bibliography
    • Alert Headline

Author(s): Joshua Dawkins, M.Pharmacol., PhD; Ema Rodrigues, DSc, MPH; Mudasir Khan, M.P.H

Joshua Dawkins, , is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.

Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables. She completed her master’s and doctoral degree (MPH, ) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.              

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Related Reports

Renal Cell Carcinoma | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma ...

View Details

Renal Cell Carcinoma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalenc...

View Details

Renal Cell Carcinoma | Current Treatment | Detailed, Expanded Analysis (US)

Market O

View Details

Renal Cell Carcinoma | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into...

View Details